TABLE 1.
In vitro studies highlighting the activation of SIT on the intrinsic apoptosis pathway.
| Cancer type | Cancer cell line(s) | Upregulated gene(s) | Downregulated gene(s) | Unaltered gene(s) | Signaling pathway(s) |
|---|---|---|---|---|---|
| Liver cancer [31] | HepG2, Huh7 | Caspase 3/9 | — | — | — |
| Liver cancer [32] | HepG2 | Caspase 3 | — | — | — |
| Liver cancer [33] | HepG2 | BAX, caspase 3/9, p53 | — | — | — |
| Liver cancer [34] | SMMC-7721 | BAX, caspase 3/9 | — | — | — |
| Cervical cancer [35] | Caski, HeLa | p53 | — | — | — |
| Cervical cancer [36] | HeLa | Caspase 3/9 | — | — | — |
| Colon cancer [37] | HT-115 | BAX, caspase 3, p53, p21 | BCL-2, PCNA, Mdm2 | — | — |
| Colon cancer [38] | COLO 320, DM | β-catenin, PCNA | — | — | |
| Colon cancer [39] | HT-116 | BAX, caspase 3/9 | BCL-2 | — | — |
| Colorectal cancer [40] | HCT116 | BAX, BAK, caspase 3, p53 | BCL-2 | — | — |
| Colon cancer [41] | HT-29 | Caspase 3 | — | — | — |
| Stomach cancer [42] | SGC-7901 | BAX, caspase 3 | BCL-2, cIAP-1 | cIAP-2 | — |
| Stomach cancer [43] | SNU216, SNU601, AGS | Caspase 3/7 | — | — | AMPK/PTEN/HSP90 |
| Breast cancer [44] | MDA-MB-231 | BAX | BCL-2 | — | ERK1/2 |
| Breast cancer [45] | MDA-MB-231 | Caspase 3/8/9 | — | — | — |
| Leukemia [46] | U937 | Caspase 3 | BCL-2 | BAX, BCL-XL, cIAP-1, cIAP-2 | — |
| Leukemia [47] | HL-60 | Caspases 3/9 | — | — | — |
| Multiple myeloma [48] | U266 | Caspase 3 | BCL-2, BCL-XL | — | AMPK/ACC; Akt/mTOR; JNK |
| Lung cancer [49] | A549, NCI-H460 | BAX, caspase 3/9, p53, p21 | BCL-2 | — | — |
| Lung cancer [50] | A549 | BAX, caspase 3/9 | BCL-2 | — | — |
| Melanoma [51] | H1_DL2 | Caspase 3 | — | — | — |
| Fibrosarcoma [52] | MCA-102 | BAX, p53, p21 | BCL-2, XIAP, cIAP-1, cIAP-2 | — | Akt/mTOR; p38 MAPK |
| Pancreatic cancer [53] | MIAPaCa-2, BXPC-3 | BAX | BCL-2 | — | NF-κB |
| Prostate cancer [54] | PC-3, DU-145 | BAX | BCL-2 | — | — |